Eagle Pharmaceuticals (EGRX) News Today → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free EGRX Stock Alerts $3.92 +0.18 (+4.81%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 22, 2024 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 22, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 21, 2024 | marketbeat.comBrandes Investment Partners LP Lowers Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Brandes Investment Partners LP reduced its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 34.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 745,080 shares of the specialty pharmaceutical company's stMay 21, 2024 | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Receives New Coverage from Analysts at StockNews.comApril 30, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual MeetingApril 15, 2024 | globenewswire.comEagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, FloridaApril 14, 2024 | investing.comEagle Pharmaceuticals faces potential Nasdaq delistingApril 13, 2024 | msn.comStocks Slightly Higher as US Mar PPI Climbs Less Than ExpectedApril 13, 2024 | msn.comStocks Mixed as Bond Yields ClimbApril 12, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KApril 12, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KFebruary 29, 2024 | msn.comEagle Pharmaceuticals to cut 36% of workforceFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX), Short Interest ReportFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX) Dividends: History, Yield and DatesFebruary 19, 2024 | marketbeat.comBrandes Investment Partners LP Boosts Stock Holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Brandes Investment Partners LP grew its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 34.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,134,363 shares of the specialty pharmacFebruary 9, 2024 | prnewswire.comEAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their OptionsFebruary 8, 2024 | stockhouse.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)February 8, 2024 | markets.businessinsider.comLevi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 8, 2024 | markets.businessinsider.comShareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRXFebruary 7, 2024 | markets.businessinsider.comClass Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & KorsinskyFebruary 6, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineFebruary 2, 2024 | stockhouse.com7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 2, 2024 | barrons.comEGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm!February 2, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $3.43 Million Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Assenagon Asset Management S.A. raised its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 66.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,February 1, 2024 | stockhouse.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 1, 2024 | marketbeat.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below Two Hundred Day Moving Average of $12.10Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below Two Hundred Day Moving Average of $12.10February 1, 2024 | markets.businessinsider.comEGRX 9-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities...January 31, 2024 | stockhouse.comINVESTOR ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EGRXJanuary 31, 2024 | barrons.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2024 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineJanuary 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRXJanuary 28, 2024 | markets.businessinsider.comEagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens BermanJanuary 23, 2024 | investing.comEagle Pharmaceuticals Inc (EGRX)January 19, 2024 | markets.businessinsider.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 18, 2024 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property PortfolioJanuary 18, 2024 | finance.yahoo.comEagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property PortfolioJanuary 14, 2024 | markets.businessinsider.comEagle Pharmaceuticals Deadline ReminderJanuary 11, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EGRXJanuary 3, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) InvestorsJanuary 2, 2024 | businesswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGRXDecember 31, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRXDecember 22, 2023 | markets.businessinsider.comEagle Pharmaceuticals Shareholder Action ReminderDecember 22, 2023 | stockhouse.comFINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the FirmDecember 17, 2023 | stockhouse.comDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmDecember 17, 2023 | markets.businessinsider.comEagle Pharmaceuticals Ongoing Deadline AlertDecember 14, 2023 | barrons.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmDecember 14, 2023 | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)December 13, 2023 | tmcnet.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)December 13, 2023 | tmcnet.comKirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Eagle Pharmaceuticals, Inc. (EGRX) Investors Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address This TSLA short trade is on a nine win hot streak (Ad)Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself. But I can promise that you’ll see all the details for yourself here. EGRX Media Mentions By Week EGRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EGRX News Sentiment▼0.870.87▲Average Medical News Sentiment EGRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EGRX Articles This Week▼42▲EGRX Articles Average Week Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KZR News CALC News ANEB News RMTI News CARM News EQ News IMMX News THTX News KRON News AEON News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EGRX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWall Street Legend Warns: "A Strange Day Is Coming to America"Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
